(Q42528711)

1 November 2017

title

The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids (English)

1 reference

1 November 2017

S Fenton

1

1 reference

1 November 2017

S Kennedy

series ordinal

2

1 reference

1 November 2017

P Moriarty

series ordinal

3

1 reference

1 November 2017

publication date

1 December 2002

1 reference

1 November 2017

1 reference

1 November 2017

volume

80

1 reference

1 November 2017

issue

6

1 reference

1 November 2017

page(s)

674-675

1 reference

Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

7 January 2021

Intralesional interferon therapy for basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

7 January 2021

Treatment of basal cell carcinoma with intralesional interferon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

7 January 2021

The nature of the suppressive effect of interferon and interferon inducers on the in vitro immune response

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

7 January 2021

Malignant epidermal tumours

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

7 January 2021

Treatment of neoplastic skin lesions with intralesional interferon

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2002.800623_3.X

7 January 2021

10.1034/J.1600-0420.2002.800623_3.X

Identifiers

DOI

1 reference

1 November 2017

1 reference